"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Xiao H, Meng X, Li Z, Fang S, Wang Y, Li J, Tang J, Ma L. Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology. Biomaterials. 2024 Dec; 311:122670.
-
Hwang YJ, Chang HY, Metkus T, Andersen KM, Singh S, Alexander GC, Mehta HB. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf. 2024 Mar; 47(3):251-260.
-
Kapoor A. The Leave Safe with DOACs Randomized Controlled Trial. J Gen Intern Med. 2024 Apr; 39(5):880.
-
Huang J, Mazer CD, Boisen ML, Tibi P, Baker RA, Chu D, Moffatt-Bruce S, Shore-Lesserson L. Safety of Andexanet Alfa Use in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2023 07; 37(7):1332-1334.
-
Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, Kelliher S, Ewins K, Comer SP, Egan K, O'Rourke E, Moran E, Petrov G, Patel A, Lennon ?, Blanco A, Kevane B, Murphy S, N? ?inle F, Maguire PB. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. J Thromb Haemost. 2021 10; 19(10):2583-2595.
-
Bigos R, Solomon E, Dorfman JD, Ha M. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients. J Surg Res. 2021 09; 265:122-130.
-
Lawlor M, Gupta A, Ranard LS, Madhavan MV, Li J, Eisenberger A, Parikh SA, Sethi SS, Masoumi A. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.
-
Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, Schmidt CM, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. J Am Coll Surg. 2021 01; 232(1):91-100.
-
Angheloiu AA, Tan Y, Ruse C, Shaffer SA, Angheloiu GO. In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution. Drugs R D. 2020 Sep; 20(3):217-223.
-
Alcusky M, Tjia J, McManus DD, Hume AL, Fisher M, Lapane KL. Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents. J Gen Intern Med. 2020 08; 35(8):2329-2337.